This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Nebivolol
Third-generation, highest-β1-selectivity beta-blocker (~321:1 over β2) with a unique β3-mediated nitric-oxide vasodilation arm — the cleanest beta-blocker for an aerobic athlete who needs one.
Aliases (6)
Overview
What is Nebivolol?
Nebivolol is a third-generation cardioselective β1-adrenergic antagonist with a unique β3-mediated nitric oxide release mechanism. FDA-approved 2007 for hypertension as Bystolic (Forest/Allergan); generic available since 2017. Has the highest β1-selectivity ratio of any beta-blocker (~321:1 over β2 in human myocardium). The β3-NO arm provides peripheral vasodilation that offsets the cardiac-output and peripheral-cooling penalty of older beta-blockers — making it dramatically better tolerated by aerobic athletes who need a beta-blocker.
Key Benefits
Cleanest beta-blocker for an aerobic athlete: preserved exercise tolerance, preserved erectile function, neutral metabolic profile, less peripheral cooling, and superior subjective tolerability vs metoprolol/atenolol/propranolol at equipotent BP-lowering doses. Mortality benefit established in elderly heart failure (SENIORS). Reverses endothelial dysfunction via NO restoration. Once-daily dosing. Generic since 2017 so cost-competitive.
Mechanism of Action
d-nebivolol enantiomer competitively antagonizes β1 cardiac adrenergic receptors with the highest selectivity ratio in the class (~321:1 over β2), slowing HR and reducing contractility. l-nebivolol enantiomer activates β3 receptors on vascular endothelium, triggering eNOS phosphorylation and nitric oxide release → peripheral vasodilation. Net effect: cardiac slowing without the peripheral vasoconstriction, cold-extremity, ED, and exercise-intolerance signature of older beta-blockers. CYP2D6 substrate — poor metabolizers (~7% Caucasians) have 8-fold higher exposure and need 2.5 mg starting dose vs standard 5 mg.
Pharmacokinetics
Research Indications
1. d-Nebivolol → β1 antagonism (cardiac slowing)
- Competitive antagonist at β1 adrenergic receptors with the highest β1-selectivity ratio of any beta-blocker — approximately 321:1 β1-ov…
2. l-Nebivolol → β3 agonism + endothelial NO release
- l-Nebivolol activates β3 adrenergic receptors located on vascular endothelial cells. - β3 activation triggers endothelial nitric oxide …
3. Antioxidant + endothelial-protective effects (downstream of NO)
- Increased NO bioavailability reduces superoxide generation, dampens NADPH oxidase, and improves endothelial function in chronic dosing.…
Why this matters vs. older beta-blockers
- Propranolol (non-selective β1+β2): blocks bronchial β2 (asthma risk), blocks skeletal-muscle β2 (impaired exercise tolerance, blunted g…
Pharmacokinetics
- Bioavailability: highly variable depending on CYP2D6 metabolizer status. Extensive metabolizers (~93% of Caucasians, ~94% of Africans, …
Why CYP2D6 status matters clinically
- The 8-fold exposure difference between EM and PM phenotypes means the same 5 mg starting dose can produce very different effects in dif…
Peptide Interactions
ACE/ARB + beta-blocker is a guideline-recommended combination for HTN with comorbidities (CAD, post-MI, HF). For an athletic HTN user, telmisartan + nebivolo…
Beta-blocker + DHP-CCB is a standard 2nd-line HTN combination; works synergistically (HR control + peripheral vasodilation).
Standard 2nd/3rd-line HTN add-on.
Standard CV-risk-reduction stack.
Additive bradycardia and AV-conduction depression — high risk of symptomatic bradyarrhythmia or block. Standard contraindication for any beta-blocker.
Redundant + risk of excessive blockade.
Raise nebivolol exposure substantially (effectively converting EM to PM phenotype). If unavoidable, halve nebivolol dose.
No significant interaction — modafinil is a CYP3A4 substrate and weak inducer; nebivolol is CYP2D6. The HR-elevation effect of modafinil is partially offset …
Synergistic for HTN; safe combo.
All safe. Mild additive on resting HR/BP via parasympathetic tone, but clinically negligible.
All safe. Citrulline + nebivolol is theoretically synergistic on NO bioavailability but no clinical signal of significance.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy. Generic Bystolic available since 2017 from major US generic manufacturers (Hetero, Glenmark, Mylan, etc.).
Branded Bystolic from US pharmacy
Forest/Allergan brand Bystolic if cost is not a concern; generics are bioequivalent and ~80-90% cheaper.
Generic vs branded bioequivalence
Generics are FDA-bioequivalent but individual response may vary slightly. Track HR/BP if switching between manufacturers.
Unbranded blister or counterfeit risk
Counterfeit cardiovascular drugs are a known risk in international gray-market sourcing. Verify pharmacy and lot if buying internationally — given easy US generic availability, gray-market is rarely necessary.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 9
Side Effects
- 1Headache (6-9%, often transient first 1-2 weeks; vasodilation-related, similar to other NO-active drugs).
- 2Fatigue (3-5%, generally less than metoprolol/atenolol at equipotent doses).
- 3Dizziness (2-4%, postural; resolves with hydration and slow positional change).
- 4Bradycardia (expected pharmacologic effect; clinically problematic in 1-3% of users).
- 5Diarrhea or GI upset.
- 6Insomnia or vivid dreams (less common than with propranolol; minimal CNS penetration).
- 7Mild edema (vasodilation-driven; transient).
- 8Erectile dysfunction (~2-5%, dramatically lower than older beta-blockers).
- 9Nausea.
When to Stop
- Severe bradycardia or AV block — relevant in users with pre-existing conduction disease.
- Symptomatic hypotension — particularly in volume-depleted users or those on multiple antihypertensives.
- Bronchospasm — rare due to high β1-selectivity but possible in severe asthmatics at high doses (selectivity is dose-dependent; β2 spillover increases at 40 mg).
- Severe hepatic impairment contraindication — nebivolol is heavily hepatically metabolized; hepatic insufficiency dramatically raises exposure.
- Withdrawal rebound — abrupt cessation after chronic use → tachycardia, HTN rebound, possible angina/MI in CAD.
- Hypoglycemia masking — partial; high β1-selectivity preserves the tachycardia warning sign somewhat, but not perfectly. Diabetics on insulin/sulfonylureas should still monitor carefully.
- Max HR cap is real but smaller than older beta-blockers at equipotent BP-lowering doses. Expect ~15-25 bpm reduction in true peak HR.
- Submax exercise tolerance preserved better than on metoprolol/atenolol. Time-to-exhaustion at zone 2-3 is closer to baseline than on older agents.
- Skeletal-muscle β2 signaling preserved. Lipolysis, glycogenolysis, and fiber recruitment less blunted.
- Peripheral perfusion preserved. Less likely to feel "muscle-starved" during prolonged efforts.
- Practical rule for athletic users: nebivolol is the cleanest beta-blocker if one is needed, but it is still a beta-blocker. There is still a real cost to peak cardiac output, and competition-day decisions should weigh that. For hypertensive athletes who must use a beta-blocker, nebivolol > all alternatives.
- Beta-blockers (general class) are prohibited by WADA only in specified shooting/precision sports (archery, shooting, billiards, darts, golf, some auto-racing, some ski-jumping events). Nebivolol shares this status.
- For combat sports, MMA, BJJ, endurance sports: nebivolol is NOT prohibited.
- The user's training is MMA — nebivolol is not banned for him under WADA rules.
References
Münzel T, Gori T 2009 — Nebivolol: the somewhat-different β-adrenergic receptor blocker (J Am Coll Cardiol)
canonical mechanism review of the β1 + β3-NO duality
View StudyFlather MD, Shibata MC, Coats AJS, et al. 2005 — Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) (Eur Heart J)
landmark HF trial, n=2,128, HR 0.86 for primary endpoint
View StudyVan Bortel LM, Fici F, Mascagni F 2008 — Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis (Am J Cardiovasc Drugs)
NEBIS / meta-analysis context for HTN efficacy
View StudyBristow MR, Nelson P, Minobe W, Johnson C 2005 — Characterization of beta1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium (Am J Hypertens)
β1-selectivity ratio data, source of the 321:1 figure
View StudyTzemos N, Lim PO, MacDonald TM 2001 — Nebivolol reverses endothelial dysfunction in essential hypertension (Circulation)
FMD endpoint, contrast with metoprolol/atenolol
View StudyDoumas M, Tsakiris A, Douma S, et al. 2006 — Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients (Asian J Androl)
switch-study showing ED reversal with nebivolol
View StudyBystolic (nebivolol) FDA prescribing information
official label, PK, dosing, contraindications
View StudyKamp O, Metra M, Bugatti S, et al. 2010 — Nebivolol: haemodynamic effects and clinical significance of combined β-blockade and nitric oxide release (Drugs)
comprehensive PK/PD review
View StudyVeverka A, Nuzum DS, Jolly JL 2006 — Nebivolol: a third-generation β-adrenergic blocker (Ann Pharmacother)
clinical pharmacology overview
View StudyMahmud A, Feely J 2008 — β-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection (Am J Hypertens)
arterial stiffness comparator data
View StudyMünzel T, Gori T 2009 mechanism review (PMC full text)
JACC review, alternate access
View StudyWADA Prohibited List 2026
sport-specific beta-blocker prohibition (precision sports only)
View StudyWikipedia — Nebivolol
mechanism, history, generic-availability timeline reference
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.